Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking

Respiratory Medicine

Volumn 103, Issue 1, 2009, Pages 85-90

  Kiri, Victor A ^a   Fabbri, Leonardo M ^b   Davis, Kourtney J ^c   Soriano, Joan B ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c GLAXOSMITHKLINE   (United States)

^d Fundacion Caubet CIMERA Illes Balears   (Spain)

Author keywords

COPD; Lung cancer; Nested case control design; Pharmacoepidemiology

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING CESSATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; ASTHMA; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MENTAL DISORDERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK; SMOKING CESSATION;

EID: 57949103178     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.07.024     Document Type: Article

References (40)

1. The British Thoracic Society. The burden of lung disease. 2nd ed. London; 2006.
2. Rowell H. Keeping people out of hospital: the challenge of reducing emergency admissions. February 2006. Available from: www.drfoster.co.uk/library/localDocuments/ReducingEmergencyAdmissions.pdf.
3. Murray C.J.L., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
4. Hansell A., Hollowell J., Nichols T., McNiece R., and Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 54 5 (1999) 413-419
5. Soriano J.B., Maier W.C., Egger P., Visick G., Thakrar B., Sykes J., et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 55 (2000) 789-794
6. Soriano J.B., Maier W.C., Visick G., and Pride N. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 17 (2001) 1075-1080
7. Soriano J.B., Vestbo J., Pride N.B., Kiri V., Maden C., and Maier W.C. Survival of COPD patients after regular use of fluticasone propionate and salmeterol in general care in the UK. Eur Respir J 20 (2002) 819-825
8. Smith C.J.P., Gribbin J., Challen K.B., and Hubbard R.B. The impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UK. Quart J Med 101 (2008) 145-153
9. Schottenfeld D. Etiology and epidemiology of lung cancer. In: Pass H. (Ed). Lung cancer: principles and practice (2000), Lippincott Williams and Wilkins, Philadelphia
10. Boyle P., Gandini S., and Gray N. Epidemiology of lung cancer: a century of great success and ignominious failure. In: Hansen H. (Ed). Textbook of lung cancer (2000), Martin Dunitz, London
11. Black R.J., Bray F., Ferlay J., and Parkin D.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33 (1997) 1075-1107
12. Tockman M.S. Other host factors and lung cancer susceptibility. In: Samet J. (Ed). Epidemiology of lung cancer (1994), Marcel Dekker, New York
13. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., and Connett J.E. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
14. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2006). Available from: www.goldcopd.com [accessed 09.05.07]
15. Brody J.S., and Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc 3 (2006) 535-537
16. Ardies C.M. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther 2 (2003) 238-246
17. Turner M.C., Chen Y., Krewski D., Calle E.E., and Thun M.J. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 176 (2007) 285-290
18. Petty T.L. Are COPD and lung cancer two manifestations of the same disease?. Chest 128 4 (2005) 1895-1897
19. Keith R.L., Cohen A.J., and Miller Y.E. From chronic obstructive lung disease to lung cancer. In: Voelkel N.F., and MacNee W. (Eds). Chronic obstructive lung disease (2002), BC Dekker, Hamilton
20. Celli B.R., MacNee W., and Committee Members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
21. Sin D.D., Lacy P., York E., and Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 760-765
22. Barnes N.C., Qiu Y.S., Pavord I.D., Parker D., Davis P.A., Zhu J., et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173 (2006) 736-743
23. Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
24. Calverley P.M.A., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
25. Rubino A., Roskell N., Tennis P., Mines D., Weich S., and Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 334 (2007) 242
26. Garcia Rodriguez L.A., and Perez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45 (1998) 419-425
27. Soriano J.B., Kiri V.A., Pride N.B., and Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2 (2003) 67-74
28. Kiri V.A., Bettoncelli G., Testi R., and Viegi G. Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. Respir Med 99 (2005) 1115-1124
29. Kiri V.A., Pride N.B., Soriano J.B., and Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 172 (2005) 460-464
30. Black C., Kaye J.A., and Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK general practice research database. BMJ 325 7361 (2002) 419-421
31. Eland I.A., Huerta-Alvarez C., Stricker B.H.C., and Garcia Rodriguez L.A. The risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol 49 (2000) 473-478
32. Nightingale A.L., and Farmer R.D. Ischemic stroke in young women: a nested case-control study using the UK general practice research database. Stroke 35 (2004) 1574-1578
33. Ito K., Ito M., Elliott W.M., Cosio B., Caramori G., Kon O.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352 (2005) 1967-1976
34. Burney P., Suissa S., Soriano J.B., Vollmer W.M., Viegi G., Sullivan S.D., et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J 22 Suppl. 43 (2003) 1-44
35. Kiri V.A., Fabbri L.M., Pride N.B., Davis K., and Soriano J.B. Combination therapy of inhaled corticosteroids and long-acting beta-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking. Eur Respir J 28 Suppl. 50 (2006) A454s
36. Kiri V.A., Fabbri L.M., Pride N.B., Davis K., and Soriano J.B. Combination therapy of inhaled corticosteroids and long-acting beta-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking. Am J Respir Crit Care Med 3 (2006) A849
37. Sin D.D., Wu L., Anderson J.A., Anthonisen N.R., Buist A.S., Burge P.S., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 (2005) 992-997
38. Yao R., Wang Y., Lemon W.J., Lubet R.A., and You M. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene 23 (2004) 7746-7752
39. Chalmers G.W., Macleod K.J., Little S.A., Thomson L.J., McSharry C.P., and Thomson N.C. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 57 (2002) 226-230
40. Parimon T., Chien J.W., Bryson C.L., McDonell M.B., Udris E.M., and Au D.H. Inhaled corticosteroids and risk of lung cancer among patients with COPD. Am J Respir Crit Care Med 175 (2007) 712-719